Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently.
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial - read this article along with other careers information, tips and advice on BioSpace
Androgen-deprivation therapy (ADT) is no longer the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC), outside of select populations with limited life expectancy, contraindications, or personal preferences, said the authors of an Oncology Grand Rounds paper in the . Instead, more-intense therapy is preferred either a combination of ADT with docetaxel or an androgen receptor signaling inhibitor, or triplet therapy with all three in fit patients with high-volume disease who prefer to intensify treatment, said Alicia Morgans, MD, and Himisha Beltran, MD, both of Dana-Farber Cancer Institute in Boston.